Loading…
Cocrystal Pharma, Inc. is projected to decline to $1.11 by 2027, a -1% move from its current price of $1.12. COCP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.08 | $1.12 | $1.16 | -0.08% |
| May 30 | $1.07 | $1.12 | $1.17 | -0.15% |
| May 31 | $1.06 | $1.12 | $1.18 | -0.23% |
| Jun 1 | $1.05 | $1.12 | $1.19 | -0.30% |
| Jun 2 | $1.04 | $1.12 | $1.20 | -0.38% |
| Jun 3 | $1.03 | $1.11 | $1.21 | -0.45% |
| Jun 4 | $1.02 | $1.11 | $1.21 | -0.53% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.02 | $1.11 | $1.21 | -0.53% |
| Week 2 | $0.9815 | $1.11 | $1.25 | -1.05% |
| Week 3 | $0.95 | $1.10 | $1.28 | -1.58% |
| Week 4 | $0.9235 | $1.10 | $1.30 | -2.09% |
| Week 5 | $0.9002 | $1.09 | $1.32 | -2.61% |
| Week 6 | $0.8792 | $1.08 | $1.34 | -3.13% |
| Week 7 | $0.86 | $1.08 | $1.35 | -3.64% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cocrystal Pharma, Inc. is a biotechnology company focused on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV.
The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc.
was headquartered in Bothell, Washington.
COCP is trading at $1.15, with a market capitalization of $15.86M, and a rank of 5024.
The forecast provides a path of modest near-term activity with stronger upside over the longer horizon. The average price projections start at $1.15 in 2026, move through $1.14 in 2027, rise to $1.21 in 2028 and to $1.42 in 2029, then reach $1.72 in 2030 and gradually trend higher to $1.93 in 2031, $1.88 in 2032, $1.89 in 2033, $1.95 in 2034, and $2.02 in 2035. By 2040 the average is $2.83 and by 2050 it is $6.06.
Maximum forecast prices reach $1.57 in 2026, $1.57 in 2027, $1.75 in 2028, $2.12 in 2029, $2.64 in 2030, $3.04 in 2031, $3.02 in 2032, $3.11 in 2033, $3.26 in 2034, $3.44 in 2035, $5.18 in 2040, and $12.30 in 2050. Corresponding ROI values start at 0 in 2026, dip to -1 in 2027, then rise to 5.6 in 2028, 23.3 in 2029, 49.6 in 2030, 67.7 in 2031, 63.1 in 2032, 64.6 in 2033, 69.4 in 2034, 75.7 in 2035, 146.4 in 2040, and 427 in 2050, with a bullish sentiment emerging from 2029 onward.
A major floor 28.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.9% away) — a key level to hold.
The nearest ceiling, 40.2% above — a clean break opens room to run.
A major ceiling 54.2% above — clearing it would confirm fresh momentum.
Key COCP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of COCP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.13 | Sell | $1.14 | Sell |
| MA 10 | $1.17 | Sell | $1.18 | Sell |
| MA 20 | $1.27 | Sell | $1.24 | Sell |
| MA 50 | $1.29 | Sell | $1.25 | Sell |
| MA 100 | $1.16 | Sell | $1.21 | Sell |
| MA 200 | $1.18 | Sell | $1.25 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.40 | Neutral |
| Stoch RSI (14) | 10.43 | Buy |
| CCI (20) | -99.43 | Neutral |
| Williams %R (14) | -96.97 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -22.22 | Sell |
| Bollinger %B (20,2) | 0.17 | Neutral |
| Stochastic %K (14) | 3.03 | Buy |
| TRIX (15) | -0.39 | Sell |
| Awesome (5,34) | -0.22 | Sell |
| Ultimate (7,14,28) | 24.20 | Buy |
| Momentum (10) | -0.19 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 1.12 | Buy |
| ADX (14) | 18.97 | Neutral |
| ATR (14) | 0.04 | Info |
The near-term technical picture is neutral, with RSI14 at 40. The stock’s moving averages sit at SMA50 of $1.28 and SMA200 of $1.18, suggesting a choppy bias around the current level.
Key support is indicated at $1.11 and resistance at $1.57, framing a 30-day range from $0.9168 to $1.44. The 30-day window reflects a modestly constrained price path, while volatility remains elevated.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.86 | $1.12 | $1.50 | 0% | Neutral | |
| $0.8657 | $1.11 | $1.52 | -1% | Neutral | |
| $0.8733 | $1.16 | $1.65 | +3% | Neutral | |
| $0.9673 | $1.32 | $1.95 | +18% | Neutral | |
| $1.15 | $1.61 | $2.43 | +44% | Bullish | |
| $1.25 | $1.79 | $2.77 | +59% | Bullish | |
| $1.19 | $1.74 | $2.77 | +56% | Bullish | |
| $1.19 | $1.77 | $2.87 | +58% | Bullish | |
| $1.18 | $1.79 | $2.95 | +60% | Bullish | |
| $1.20 | $1.86 | $3.11 | +66% | Bullish | |
| $1.53 | $2.58 | $4.63 | +131% | Bullish | |
| $2.73 | $5.33 | $10.56 | +376% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.86 | $1.12 | $1.32 | +0.00% |
| June 2026 | $0.9217 | $1.09 | $1.32 | -2.95% |
| July 2026 | $0.8776 | $1.05 | $1.29 | -3.82% |
| August 2026 | $0.8928 | $1.07 | $1.33 | +2.53% |
| September 2026 | $0.9059 | $1.09 | $1.38 | +2.14% |
| October 2026 | $0.8843 | $1.08 | $1.36 | -1.80% |
| November 2026 | $0.8975 | $1.10 | $1.40 | +2.03% |
| December 2026 | $0.9472 | $1.16 | $1.50 | +6.07% |
Click any year to see its month-by-month COCP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cocrystal Pharma, Inc.'s 2026 outlook centres on $1.12, within a $0.86 to $1.50 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, COCP could reach as high as $1.52, with a base case around $1.11 and support toward $0.8657 — roughly -1% from $1.12. A consolidation phase looks the most probable path here.
Expect COCP to range from $0.8733 to $1.65 through 2028. The $1.16 average target implies a +3% move from current prices. That is up +4% on the projected 2027 average. Price action looks broadly range-bound.
The COCP price prediction for 2029 points to an average of $1.32 (low $0.9673, high $1.95) — a potential gain of +18% on today's $1.12. A consolidation phase looks the most probable path here.
In 2030, COCP is projected to trade between $1.15 and $2.43, averaging $1.61 — a potential gain of +44% from today's $1.12. That is up +22% on the projected 2029 average. Momentum favours further upside here.
Cocrystal Pharma, Inc.'s 2031 outlook centres on $1.79, within a $1.25 to $2.77 range. That is up +11% on the projected 2030 average. That marks a +59% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, COCP could reach as high as $2.77, with a base case around $1.74 and support toward $1.19 — roughly +56% from $1.12. Momentum favours further upside here.
Expect COCP to range from $1.19 to $2.87 through 2033. The $1.77 average target implies a +58% move from current prices. That is up +2% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The COCP price prediction for 2034 points to an average of $1.79 (low $1.18, high $2.95) — a potential gain of +60% on today's $1.12. Momentum favours further upside here.
In 2035, COCP is projected to trade between $1.20 and $3.11, averaging $1.86 — a potential gain of +66% from today's $1.12. That is up +4% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Cocrystal Pharma, Inc.'s 2040 outlook centres on $2.58, within a $1.53 to $4.63 range. That is up +39% on the projected 2035 average. That marks a +131% change versus current levels. Momentum favours further upside here.
By 2050, COCP could reach as high as $10.56, with a base case around $5.33 and support toward $2.73 — roughly +376% from $1.12. Buyers look set to stay in control over this stretch.
Investing $1,000 in COCP today (≈ 892.857143 COCP) could be worth
$4,762.97
+$3,762.97 (+376%) by 2050 · US Dollar
Based on the average projected COCP price of $5.33 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in COCPwould be worth at today's price.
$1,000 invested in COCP on May 27, 2025 (≈ 704.225373 COCP) would be worth
$788.73
-$211.27 (-21.1%) today · 0.79× · US Dollar
Based on a COCP entry price of $1.42 vs. today's $1.12.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.11 | $1,009.01 | +0.9% |
| 1 month ago | $1.4 | $800 | -20.0% |
| 3 months ago | $1.06 | $1,056.6 | +5.7% |
| 6 months ago | $1.06 | $1,056.6 | +5.7% |
| 1 year ago | $1.42 | $788.73 | -21.1% |
| All time (5.0y) ago | $13.92 | $80.46 | -92.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our COCP forecast.
Our base-case forecast reaches $2.20 around 2040.
Implied market cap at $2.20: $30.33M
The multi-year outlook is bullish in the later years, with notable upside by 2030 and beyond. The 2030 average is $1.72 with a 49.6 ROI, and the 2040 average rises to $2.83 with a 146.4 ROI, followed by a 2050 average of $6.06 with a 427 ROI. The forecast shows continued bullish sentiment from 2029 onward, supported by higher max forecasts such as $2.12 in 2029 and $12.30 in 2050.
These figures imply meaningful upside potential over the long term, but they are estimates and not guarantees. The extent of future returns will depend on a range of factors, including clinical progress, regulatory outcomes, and market conditions, among others.
Tap a question to reveal the answer.
2030 avg $1.72; max $2.64; min $1.21; ROI 49.6; sentiment BULLISH.
Forecasts show a neutral path in 2026–2027, then rising into a bullish trajectory from 2029 onward, with 2030–2050 averages and outsized potential by 2050 (avg $6.06; max $12.30; ROI up to 427; sentiment BULLISH). Note that these are estimates, not guarantees.
2040 max $5.18; 2040 avg $2.83; ROI 146.4; sentiment BULLISH.
Current price $1.15; market cap $15.86M.
30-day range low $0.9168; high $1.44.
Cocrystal Pharma, Inc. Community Discussion
0Share your Cocrystal Pharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.